{"title":"癌症治疗的新视野和挑战","authors":"M. Tan","doi":"10.19080/ctoij.2021.20.556037","DOIUrl":null,"url":null,"abstract":"Cancer is one of the top causes of death, and a huge barrier for high-quality life globally [1]. In 2020 alone, there were 19.3 million new cases, of which close to 10 million were fatal [2]. It is estimated that cancer-related healthcare costs would amount to $232.9 billion between 2020 and 2030 [3]. Therefore, it is imperative to develop new and improved medicines for cancer therapy to enhance the patients’ quality of life lower the mortality rates. Currently, an increasing number of prospective medicines and novel therapies are being tested in clinical trials, some of which have benefited the enrolled patients. Here, we will review the eve and challenges of cancer therapy, with particular focus on immunotherapy and targeted therapy.","PeriodicalId":360247,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"27 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Horizons and Challenges of Cancer Therapy\",\"authors\":\"M. Tan\",\"doi\":\"10.19080/ctoij.2021.20.556037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cancer is one of the top causes of death, and a huge barrier for high-quality life globally [1]. In 2020 alone, there were 19.3 million new cases, of which close to 10 million were fatal [2]. It is estimated that cancer-related healthcare costs would amount to $232.9 billion between 2020 and 2030 [3]. Therefore, it is imperative to develop new and improved medicines for cancer therapy to enhance the patients’ quality of life lower the mortality rates. Currently, an increasing number of prospective medicines and novel therapies are being tested in clinical trials, some of which have benefited the enrolled patients. Here, we will review the eve and challenges of cancer therapy, with particular focus on immunotherapy and targeted therapy.\",\"PeriodicalId\":360247,\"journal\":{\"name\":\"Cancer Therapy & Oncology International Journal\",\"volume\":\"27 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Therapy & Oncology International Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.19080/ctoij.2021.20.556037\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Therapy & Oncology International Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/ctoij.2021.20.556037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Cancer is one of the top causes of death, and a huge barrier for high-quality life globally [1]. In 2020 alone, there were 19.3 million new cases, of which close to 10 million were fatal [2]. It is estimated that cancer-related healthcare costs would amount to $232.9 billion between 2020 and 2030 [3]. Therefore, it is imperative to develop new and improved medicines for cancer therapy to enhance the patients’ quality of life lower the mortality rates. Currently, an increasing number of prospective medicines and novel therapies are being tested in clinical trials, some of which have benefited the enrolled patients. Here, we will review the eve and challenges of cancer therapy, with particular focus on immunotherapy and targeted therapy.